CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

Novartis, Vertex and Ipsen extend pharma M&A spree from 2026's first half

Positive
AI Analysis

Summary

Novartis, Vertex, and Ipsen announced acquisitions in early July 2026, with multiple deals valued at up to $12.6 billion combined, continuing the active M&A activity in the biopharma sector.

Importance:7/10
Sentiment:
0.50
M&Aacquisitionspharma consolidation
Related Companies

Read the original article

Published by Endpoints News on July 7, 2026 2:54 PM

Read Original